Clinical Trials Logo

Clinical Trial Summary

RATIONALE:

Cardiac resynchronization therapy (CRT) is known to improve cardiac performance and to reduce morbidity and mortality in reduced-ejection fraction heart failure (HFrEF) despite optimal medical therapy (OMT). Several studies have shown that patients with with left bundle branch block (LBBB) respond favourably to CRT, whereas there is less certainty about non-LBBB morphology.

Specifically, whether patients with right bundle branch block (RBBB) and HFrEF benefit from CRT is unclear. Some studies suggest lack of favourable outcomes. It follows from this that VVI implantable defibrillator are implanted in most RBBB patients.On the other hand right ventricular bifocal stimulation could be useful as an alternative approach in patient with RBBB. It consists of two endocardial leads implanted in right ventricle. The first lead is implanted in His bundle area, and the second lead is in the right ventricle apex. In this way bifocal pacing could decrease the inter- and intraventricular delays, thus improving left ventricular hemodynamics. However no specifically randomized studies are designed to date.

PURPOSE:

To demonstrate the superiority of right ventricular bifocal stimulation over placebo (VVI implantable defibrillator) in RBBB and HFrEF despite OMT.

DESIGN Multicenter prospective randomized, double blind cross-over study. MASKING Investigator responsible for device programming is masked from having knowledge about clinical, functional, and echocardiographic data. On the other hand echocardiographist is masked from having knowledge about stimulation mode. Patients are masked from having knowledge about their clinical, functional, and device data.

POPULATION At least fifty patients would be enrolled. The enrollment period should be one year. Study overall duration should be two years.

ELIGIBILITY CRITERIA RBBB and HFrEF (left ventricular ejection fraction ≤35%) in sinus rhythm, in NYHA class II-III or ambulatory IV despite OMT.

EXCLUSION CRITERIA

-Refusal or withdrawal of informed consent.Renal failure (glomerular filtration rate ≤ 60 ml/min).Life expectancy < 12 months.Active neoplasm.Permanent atrial fibrillation.40 days following acute coronary syndrome.Atrio-ventricular block (from second degree AV block).Valvular heart disease with surgery indications.

PROTOCOL Each patient undergoes baseline assessment. Pharmacological therapy, hospitalization,NYHA functional class, QRS complex informations, type of heart disease and comorbidities are collected. Quality of life (QOL) is defined by Minnesota Living with Heart Failure questionnaire. Functional capacity is assessed by 6MWT (optionally by cardiopulmonary exercise test). Trans-thoracic echocardiogram is performed, analyzing: left-ventricle diameters and volumes, left-ventricle ejection fraction (LVEF), left atrial diameter and area, TAPSE,valvulopathy,systolic pulmonary artery pressure. All patients undergo bifocal right ventricular resynchronization therapy: right atrial lead is implanted, whereas the first ventricular lead is placed in His bundle area, and the second ventricular lead in the right ventricle apex. Then the leads are connected to the respective channels of a CRT-D generator.After the implant, all devices are programmed in VVI mode. After the first 40±10 days (first f-up) patients are 1:1 randomized to VVI mode 40 beats/minute (placebo arm) or bifocal DDD-mode 60 beats/minute (with VV delay 0 msec and optimal AV delay). After six months (second f-up) a clinical and instrumental assessment equal to baseline is performed, as well as devices electrical parameters control. Then arms cross-over is performed (from VVI-mode to bifocal DDD-mode and vice versa). At 12 months (end of follow-up) an evaluation equal to that performed at 6 months is assessed. Echocardiographic data are unravelled to the investigator responsible for device programming. In this way the stimulation mode able to determine the best clinical improved (VVI or bifocal DDD mode) is programmed and the study closes.

PRIMARY ENDPOINT The main assumption is that bifocal stimulation can increase of at least 20% the distance walked during 6MWT in respect of baseline and VVI-mode.The primary endpoint is the distance walked (expressed by meters) during 6MWT, as assessed at baseline, 6-months follow-up and 12 months follow up. Specifically changes in 6MWT observed during bifocal DDD-mode compared to baseline and to VVI mode would be significative if there is an increase of at least 20%.

SECONDARY ENDPOINT

Secondary endpoint is bifocal stimulation therapy response, defined by at least one of the following criteria, evaluated at baseline, 6-months follow-up and 12 months-follow-up in comparison to baseline and VVI mode:

NYHA functional class improvement; changes in 6MWT, defined by an increase in distance walked major or equal to 30%; LVEF improvement major or equal to 25%;Left ventricular telesystolic volume reduction major or equal to 15%


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03524001
Study type Interventional
Source Azienda Ospedaliero Universitaria Maggiore della Carita
Contact Gabriele Dell'Era, MD
Phone 03213733590
Email gdellera@gmail.com
Status Recruiting
Phase N/A
Start date February 1, 2018
Completion date July 10, 2020

See also
  Status Clinical Trial Phase
Completed NCT02113033 - VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients Phase 2
Recruiting NCT03209180 - Immediate Release Versus Slow Release Carvedilol in Heart Failure Phase 4
Completed NCT01922089 - Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients Phase 2
Not yet recruiting NCT03213821 - Safety and Efficacy of High Protein Diet Versus GFR Based Protein Diet in Heart Failure Patients With Renal Insufficiency N/A
Recruiting NCT03141567 - LYmphangiogenesis FacTors in Heart Failure States N/A
Not yet recruiting NCT03332888 - Safety of HMA-CD20 in Patients With HFrEF Phase 2
Recruiting NCT03387813 - Hemodynamic-GUIDEd Management of Heart Failure N/A
Recruiting NCT03235700 - Hyperemic Efficacy of IV Adenosine in HFrEF N/A
Recruiting NCT03198585 - Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction Phase 2
Not yet recruiting NCT03072693 - Daily Ambulatory Remote Monitoring System For Post-Dischage Management Of ADHF N/A
Not yet recruiting NCT03136029 - Exercise and NO in HFrEF Early Phase 1
Not yet recruiting NCT03119623 - Comparing ARNI With ACE Inhibitor on Endothelial Function Phase 4
Recruiting NCT03061747 - Multi-centre Observational Registry on Patients With Implantable Devices Remotely Monitored N/A
Recruiting NCT03317314 - Cardiopulmonary Interactions in Patients With Heart Failure N/A
Recruiting NCT03334188 - Electronic Health Record-leveraged, Patient-centered, Intensification of Chronic Care for HF N/A
Not yet recruiting NCT03359967 - Changes in Intrathoracic Impedance During Sacubitril/Valsartan Treatment N/A
Active, not recruiting NCT02661217 - Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event Phase 4
Recruiting NCT03289637 - Supplementation With Vitamin D to Patients With Heart Failure (D-Heart). N/A
Recruiting NCT03380156 - Effect of Transcutaneous Vagal Stimulation (TVS) on Endothelial Function and Arterial Stiffness in HFrEF N/A
Completed NCT01035255 - This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure Phase 3